What is Hyperfine, Inc. (HYPR)?

Hyperfine, Inc. (HYPR) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of HYPR?

The current price of HYPR is $0.74. Prices are updated in real time on Stocks360.

What is HYPR's price-to-earnings (PE) ratio?

HYPR's trailing twelve-month PE ratio is -1.94, based on current price and earnings per share data available on Stocks360.

What is HYPR's market capitalization?

HYPR's market capitalization is $67,662,678.00, placing it in the small-cap tier.

Hyperfine, Inc. (HYPR)

Stock analysis · NASDAQ · Healthcare · Medical - Devices

$0.74

Market Cap

$67.66M

PE (TTM)

-1.94

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.46

Day Range

$0.73 – $0.78

52-wk Range

$0.70 – $1.94

Avg Volume

N/A

Volume

679.27K

Hyperfine, Inc. (HYPR) is a publicly traded company in the Healthcare sector. Latest price: $0.74. Market cap $67.66M. Trailing PE -1.94. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $1.11 2026-10-29 · $0.74 (-33.01%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.09 vs est. $-0.09

Beat by $0.00

Next Earnings

Nov 9, 2026

EPS estimate $-0.08

Proprietary Signals

Signal snapshot temporarily unavailable.

About Hyperfine, Inc.

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.94×
P/S (TTM)	4.09×
P/B	2.02×
P/FCF (TTM)	-2.46×
EV / EBITDA	-1.14×
EV / Sales	2.27×
Earnings Yield	-46.96%
Free Cash Flow Yield	-40.69%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$37.62M
Revenue (TTM)	$16.54M
Net Income (TTM)	-$31.78M
Free Cash Flow (TTM)	-$26.91M
Net Debt	-$30.05M
Working Capital	$49.61M
Gross Margin	51.41%
Operating Margin	-203.27%
Net Margin	-210.75%
Return on Equity	-100.30%
Return on Invested Capital	-62.78%